vorinostat and Lymphoma of Mucosa-Associated Lymphoid Tissue

vorinostat has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (2)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Overall Response Rate (Complete and Partial Response)

Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment

Progression-free Survival

ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress elapse, up to 1 year after the start of treatment

Number of Participants With Grade 3 and 4 Toxicities

Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment

2-Year Overall Survival

Estimated using the product-limit method of Kaplan and Meier. (NCT00253630)
Timeframe: Until Death from any cause, up to 2 years

2-Year Progression Free-Survival

Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir. (NCT00253630)
Timeframe: Until death or progression, up to 2 years

Response Rate

Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR. (NCT00253630)
Timeframe: Up to 3 years

Number of Participants With Adverse Events

Grades 3 & 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. (NCT00253630)
Timeframe: Up to 3 years

Trials

2 trials available for vorinostat and Lymphoma of Mucosa-Associated Lymphoid Tissue